A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary reportS. Kim, Andrew S. Brohl, Jane L. Messina et al.|Annals of Oncology|2019Cited by 5